Alpha 2.0
Login Register
» Authors » Xijier Qiaolongbatu

Xijier Qiaolongbatu

Explore the profile of Xijier Qiaolongbatu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 14
Followers 0
Related Specialties
Pharmacology
General Medicine
Toxicology
Top 10 Co-Authors
Guorong Fan
Zhenghua Wu
Han Qu
Cui Ma
Yuefen Lou
Xucong Huang
Jiaqi Wu
Wenjuan Zhao
Lili Jing
Li Wang
Published In
Drug Des Devel Ther
J Ethnopharmacol
Toxicol Appl Pharmacol
Sci Rep
Medicina (Kaunas)
Affiliations
Soon will be listed here.
Recent Articles
1.
Alisol A, the Eye-Entering Ingredient of , Relieves Macular Edema Through TNF-α as Revealed by UPLC-Triple-TOF/MS, Network Pharmacology, and Zebrafish Verification
Shen R, Cheng K, Li G, Pan Z, Qiaolongbatu X, Wang Y, et al.
Drug Des Devel Ther . 2024 Aug; 18:3361-3382. PMID: 39100223
Purpose: (AO, (Sam). Juzep) has been widely employed for the treatment of macular edema (ME) in traditional Chinese medicine due to its renowned water-relief properties. Nonetheless, the comprehensive investigation of...
2.
Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real-World Pharmacovigilance and Randomized Clinical Trials
Qu H, Wu J, Ma C, Qiaolongbatu X, Song X, Feng T, et al.
Clin Pharmacol Ther . 2023 Apr; 114(1):201-210. PMID: 37087633
Eltrombopag is clinically approved for use in immune thrombocytopenia (ITP), chronic hepatitis C-related thrombocytopenia, and aplastic anemia and suitable for children; however, data on its overall safety profile are scarce....
3.
Exploring the components and mechanisms of Shen-qi-wang-mo granule in the treatment of retinal vein occlusion by UPLC-Triple TOF MS/MS and network pharmacology
Zhao Y, Ma C, Qiu Q, Huang X, Qiaolongbatu X, Qu H, et al.
Sci Rep . 2023 Apr; 13(1):5330. PMID: 37005436
This study aimed to explore the substance basis and mechanisms of Shen-qi-wang-mo Granule (SQWMG), a traditional Chinese medicine prescription that had been clinically utilized to treat retinal vein occlusion (RVO)...
4.
The Therapeutic Mechanism of Schisandrol A and Its Metabolites on Pulmonary Fibrosis Based on Plasma Metabonomics and Network Analysis
Qiaolongbatu X, Zhao W, Huang X, Qian F, Yang X, Wu J, et al.
Drug Des Devel Ther . 2023 Feb; 17:477-496. PMID: 36814892
Background: Schisandrol A (Sch A) is the main active ingredient of (Turcz.) Baill. Our previous study showed that Sch A has anti-pulmonary fibrosis (PF) activity, but its metabolic-related mechanisms of...
5.
The Role and Mechanism of Hyperoside against Depression-like Behavior in Mice via the NLRP1 Inflammasome
Song A, Wu Z, Zhao W, Shi W, Cheng R, Jiang J, et al.
Medicina (Kaunas) . 2022 Dec; 58(12). PMID: 36556951
Background And Objectives: (HP) is widely used for depressive therapy. Nevertheless, the antidepressant effect and potential mechanism of hyperoside (Hyp), the main active component of HP, have not been determined....
6.
A systematic comparison of anti-angiogenesis efficacy and cardiotoxicity of receptor tyrosine kinase inhibitors in zebrafish model
Ma C, Wu Z, Wang X, Huang M, Wei X, Wang W, et al.
Toxicol Appl Pharmacol . 2022 Jul; 450:116162. PMID: 35830948
Pathological angiogenesis is fundamental to progression of cancerous tumors and blinding eye diseases. Anti-angiogenic receptor tyrosine kinase inhibitors (TKIs) are in broad use for the treatment of these diseases. With...
7.
Schisandrol A, the main active ingredient of Schisandrae Chinensis Fructus, inhibits pulmonary fibrosis through suppression of the TGF-β signaling pathway as revealed by UPLC-Q-TOF/MS, network pharmacology and experimental verification
Wu Z, Jia M, Zhao W, Huang X, Yang X, Chen D, et al.
J Ethnopharmacol . 2022 Jan; 289:115031. PMID: 35091014
Ethnopharmacological Relevance: Schisandra chinensis decoction derived from the book of Waitai Miyao (Tao Wang, Tang dynasty) is often used in the treatment of idiopathic pulmonary fibrosis (IPF), which is included...